Authors: Danielson, BR Skold, AC Azarbayjani, F

Citation: Br. Danielson et al., Class III antiarrhythmics and phenytoin: Teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage, CUR PHARM D, 7(9), 2001, pp. 787-802

Authors: Skold, AC Danielsson, BR

Citation: Ac. Skold et Br. Danielsson, Developmental toxicity in the pregnant rabbit by the class III antiarrhythmic drug sotalol, PHARM TOX, 88(1), 2001, pp. 34-39

Authors: Skold, AC Wellfelt, K Danielsson, BR

Citation: Ac. Skold et al., Stage-specific skeletal and visceral defects of the I-Kr-Blocker almokalant: Further evidence for teratogenicity via a hypoxia-related mechanism, TERATOLOGY, 64(6), 2001, pp. 292-300

Authors: Danielsson, B Skold, AC Azarbayjani, F Ohman, I Webster, W

Citation: B. Danielsson et al., Pharmacokinetic data support pharmacologically induced embryonic dysrhythmia as explanation to fetal hydantoin syndrome in rats, TOX APPL PH, 163(2), 2000, pp. 164-175

Authors: Skold, AC Danielsson, BR

Citation: Ac. Skold et Br. Danielsson, Developmental toxicity of the class III antiarrhythmic agent almokalant inmice - Adverse effects mediated via induction of embryonic heart rhythm abnormalities, ARZNEI-FOR, 50(6), 2000, pp. 520-525

Authors: Wellfelt, K Skold, AC Wallin, A Danielsson, BR

Citation: K. Wellfelt et al., Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species, REPROD TOX, 13(2), 1999, pp. 93-101